MEI Pharma Inc (NASDAQ:MEIP) is trading in a very narrow range in early session on Thursday. The stock has been witnessing a weak trend since over the past month with a fall of around 7%.
MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program
- announced clinical data from a Phase 1b study of zandelisib, an investigational selective phosphatidylinositol 3-kinase delta (“PI3K”) inhibitor in clinical development for the treatment of B-cell malignancies, and the trial design of COASTAL, a Phase 3 study of zandelisib in combination with rituximab, will be highlighted in poster presentations at the 16th International Conference on Malignant Lymphoma (16-ICML) to be held June 18 – 22, 2021.
As of 11:11, MEIP stock down by 0.16% to $3.15 with more than 82K shares traded hands, compared to its average volume of 652K shares. The stock has moved within a range of $3.1150 – 3.1900 after opening the trade at $3.19.
|CCI20||126.7273||Buy||Chaikin Money Flow||-0.1512||Sell|
|MACD||-0.0445||Sell||Money Flow Index||75.6859||Buy|
|STOCH (14,3)||90.1961||OverBought||STOCH RSI||1.0000||OverBought|